Clinical

Dataset Information

0

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers


ABSTRACT: The purpose of the Phase 1/2a study is to evaluate the safety and tolerability of SNK01 in combination with trastuzumab or cetuximab in order to determine the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D), and the preliminary efficacy for each combination regimen.

DISEASE(S): Uterine Cervical Neoplasms,Triple Negative Breast Neoplasms,Colorectal Cancer,Her-2 Protein Overexpression,Her2-positive Gastric Cancer,Non Small Cell Lung Cancer,Triple Negative Breast Cancer,Urinary Bladder Neoplasms,Endometrial Neoplasms,Breast Neoplasms,Lung Neoplasms,Ovarian Cancer,Neoplasm Metastasis,Esophageal Neoplasms,Gastric Cancer,Advanced Solid Tumor,Endometrium Cancer,Colorectal Neoplasms,Carcinoma, Non-small-cell Lung,Her2-positive Breast Cancer,Ovarian Neoplasms,Pancreatic Neoplasms,Stomach Neoplasms,Head And Neck Squamous Cell Carcinoma,Solid Tumor,Sarcoma,Cervical Cancer,Advanced Cancer,Bladder Cancer,Pancreatic Cancer,Breast Cancer,Carcinoma, Squamous Cell,Squamous Cell Carcinoma Of Head And Neck,Esophageal Cancer,Metastatic Cancer,Egf-r Positive Non-small Cell Lung Cancer,Cancer

PROVIDER: 2345115 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2016-07-31 | E-GEOD-75087 | biostudies-arrayexpress
2015-10-06 | GSE66305 | GEO
2015-10-06 | GSE66398 | GEO
2015-04-21 | E-GEOD-55005 | biostudies-arrayexpress
2020-06-01 | PXD010574 | Pride
2016-03-31 | E-GEOD-62327 | biostudies-arrayexpress
2016-12-31 | GSE58984 | GEO
2015-10-19 | E-GEOD-55348 | biostudies-arrayexpress
2015-10-19 | GSE55348 | GEO
2016-03-31 | GSE62327 | GEO